Decrease of luciferase activity.

<p>The expression level of luciferase was postoperatively observed using a noninvasive living image acquisition IVIS system. Accumulation of MSCs in the remnant liver. <b>A</b>. Most of the MSCs became trapped in the remnant liver. Thereafter, the luciferase activity diminished with time. <b>B</b>. The largest level of luciferase was 187272±119507 photons/sec/cm²/sr (sr = units of solid angle or steradian). (24 h vs. 168 h: <i>P</i><0.03; 24 h vs. 120 h: P<0.05; 72 h vs. 168 h: P<0.05).</p

Remnant liver volume changes.

<p>The liver regeneration rate is expressed as remnant liver weight/estimated whole liver weight.</p

Characterization of BM-MSCs by expression of CD29⁺, CD31⁻, CD34⁻, and CD105⁺.

<p><b>A</b>. Bright-field image. <b>B–C</b>. CD29 and CD105 surface antigens are positive. <b>D</b>. CD31 surfice antigen is negative, <b>E</b>. CD34 surfice antigen negative.</p

Histopathological changes and Suzuki Score.

<p>Hematoxylin eosin staining of I/R-injured liver sections from the MSC group (<b>A</b>. left panel) and the Control group (<b>B</b>. right panel). <b>C</b>. The lower levels of congestion, vacuolization, and necrosis were seen in the MSC group. Suzuki scores = (MSC group vs. Control group: 1.4±1.3 vs. 3.9±1.7, <i>p</i><0.03).</p

A new rat model of major hepatectomy with I/R injury.

<p>A new rat model of major hepatectomy with I/R injury.</p

Minimal TUNEL-positive hepatocytes by BM-MSC transplantation.

<p>TUNEL staining of I/R-injured liver sections from the MSC group (<b>A</b>. upper panel) and the Control group (<b>B</b>. lower panel). <b>C</b>. Quantification of TUNEL-positive hepatocyte nuclei was assessed by calculating the mean of the number of TUNEL-positive hepatocytes in 10 random high-power fields per animal. Abbreviations: CV, central vein; PV, portal vein.</p

MOESM2 of Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

Additional file 2: Figure S1. The ROC curve analysis of the performance of 18F-FDG-PET parameters for predicting KRAS mutation status. (a) Maximum standardized uptake value (SUVmax), (b) metabolic tumor volume (MTV), and (c) total lesion glycolysis (TLG). Note the high area under the ROC curve (AUC), 95% confidence interval (CI), and cutoff value (red font). ROC receiver operating characteristic, AUC area under the curve

MOESM1 of Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

Additional file 1: Table S1. Univariate and Multivariate analyses of prognostic factors for overall survival

Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer-3

Ells were infected with Ad5GFP or Ad5MK at various MOIs. After 1, 3, and 5 days, the number of viable cells was counted.<p><b>Copyright information:</b></p><p>Taken from "Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer"</p><p>http://www.jeccr.com/content/27/1/30</p><p>Journal of Experimental & Clinical Cancer Research : CR 2008;27(1):30-30.</p><p>Published online 21 Aug 2008</p><p>PMCID:PMC2529268.</p><p></p

Characteristics of patients with chronic HBV infection analyzed in this study.

†<p>Values are median (range).</p>*<p>P = 0.042.</p